United-Guardian, Inc. — FY 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012. This filing reports annual results, not standalone fourth-quarter results. Comparisons below are with FY 2011.
Business context
United-Guardian manufactures and markets personal-care and cosmetic ingredients, pharmaceuticals, medical products, and specialty industrial products through its Guardian Laboratories division. It reports one business segment. LUBRAJEL products generated 86.5% of FY 2012 revenue; RENACIDIN generated 7.6%. Approximately 66% of sales were to foreign customers.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 | Change / context |
|---|---|---|---|
| Net sales | $13.83 million | $14.34 million | Down $512,748, or 3.6% |
| Gross profit / margin | $8.61 million / 62.3% | $8.69 million / 60.6% | Margin improved with a more favorable product mix |
| Operating income / margin | $6.10 million / 44.1% | $6.14 million / 42.8% | Operating income down slightly |
| Net income | $4.83 million | $4.72 million | Up 2.4% |
| diluted EPS | $1.05 | $1.03 | Weighted average shares unchanged at 4,596,439 |
| Cash from operations | $5.38 million | $4.44 million | Increase primarily reflected lower receivables and inventory |
| Cash and cash equivalents | $1.75 million | $1.09 million | |
| Marketable securities | $7.74 million | $9.30 million | |
| Working capital / current ratio | $11.80 million / 15.25:1 | $12.90 million / 12.97:1 | Working capital fell 8.5%; current ratio rose |
Total assets were $13.86 million and stockholders’ equity was $12.84 million at year-end. Current liabilities were $827,508; the filing reports no borrowings or line of credit. The company said working capital was sufficient for the next fiscal year and disclosed no material capital-expenditure commitments.
Cash used in financing was $6.25 million, all dividends, compared with $3.68 million in 2011. The 2012 distributions included regular dividends of $0.42 and $0.44 per share and a $0.50-per-share special dividend. Investing activities provided $1.53 million, mainly reflecting marketable-security sales.
Material changes and unusual items
- Personal-care sales rose 2.2%, primarily from increased sales to ASI and higher LUBRAJEL sales. Medical sales were broadly flat; industrial and miscellaneous sales increased 14.7% from a small base.
- Pharmaceutical sales fell 34.1%, mainly because the RENACIDIN supplier curtailed production beginning in May 2012. United-Guardian depleted its inventory by August and could not fill orders. RENACIDIN represented 7.6% of revenue, versus 12.7% in 2011.
- The supplier-related product mix shift, together with higher LUBRAJEL sales and lower insurance costs, helped reduce cost of sales to 37.7% of sales from 39.4%.
- Other income included a $518,050 RENACIDIN supplier damage settlement in 2012; 2011 included a separate $385,182 settlement. The 2012 balance sheet lists $518,050 as a settlement receivable at year-end, while the filing also describes the amount as paid. Investors should verify the timing and cash receipt.
- Research and development expense was $693,000, up from $637,000. Operating expenses overall declined 1.7%.
Outlook, risks, and contingencies
- The current RENACIDIN supplier projected production resumption in Q3 2013, but the company cautioned that availability was not assured. The supply contract expires in January 2014. A replacement supplier and a 30 mL single-dose presentation are planned, subject to FDA approval; the company estimated approval and market launch in the second half of 2014. A supply gap could persist until then.
- Management expected 2013 R&D costs to be comparable to 2012, or approximately $693,000. It anticipated sales potential from new LUBRAJEL TF, whose initial shipments began late in 2012, and hoped to begin sales of LUBRAJEL NATURAL in 2013. These are expectations, not guarantees.
- Key risks include dependence on the RENACIDIN contract manufacturer, competition and product substitution, regulatory approval requirements, customer and distributor concentration, raw-material availability, and economic weakness in certain markets. Two customers accounted for approximately 62% of FY 2012 revenue and 52% of year-end receivables. Five raw-material vendors represented 77% of raw-material purchases.
- ASI is the largest marketing partner; its agreement was extended through December 31, 2013. Several other foreign distributor arrangements were verbal or expired and could be terminated. The company cited no material environmental impact, no legal proceedings, and no off-balance-sheet arrangements.
- The independent auditor gave an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Whether RENACIDIN production resumed as projected, whether replacement-supplier FDA approval was obtained, and the actual timing of restored sales.
- Whether the $518,050 settlement receivable was collected and whether further supplier payments were received under the agreement.
- Renewal or replacement of the ASI agreement and the status of other distributor arrangements, given the concentration of revenue through a small number of customers and partners.
- Whether new products and geographic expansion offset the ongoing supply, competitive, regulatory, and raw-material risks.
- The sustainability of dividends, particularly the 2012 special dividend, alongside operating cash generation and investment-portfolio levels.